Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

You may be eligible if

• Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate
• Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy
• Detectable metastases
• ECOG performance status ≤2 (Performance status of 3 if due to bone pain)
• Any Gleason score
• Only one prior treatment with systemic chemotherapy
• No prior treatment with gene therapy
• No prior immunotherapy for prostate cancer
• Taxane naïve
• Experiencing cancer-related pain